INT/ICR EHE research expanded

INT ICR

We are delighted to be able to share the exiting news that the EHERCC, with the EHE Foundation in the USA, has confirmed funding for an expansion of the collaborative EHE research being conducted by ‘The Instituto Nazionale Tumori’ (INT) in Milan, Italy and ‘The Institute of Cancer Research’ (ICR) in London, UK. This expansion is a three-year project with three key objectives:

Objective 1:    The generation and characterization of patient-derived preclinical models of EHE to assess the activity of anticancer agents and identify/validate novel therapeutic targets. This will involve the generation of four or more additional PDX models of EHE from patients with different variants of the disease. The models will then be used to assess the activity of drugs relevant for the disease as monotherapies and in drug combinations;

Objective 2:    The validation of circulating microRNA that have been shown to be differentially expressed in EHE patients compared to healthy donors; and

Objective 3:    Radiological features and response assessment involving the collation and review of a comprehensive collection of the radiological assessments performed at the foreseen timepoints by all patients enrolled. Evaluation of the imagery will be used to try and gain greater definition of radiological progression and the assessment of treatment response in EHE which remain major challenges.

INT and ICR together are conducting this multi-faceted research programme, building on and broadening their existing EHE research collaboration that has been in progress over the last 18 months. The project is developing critical PDX models (PDX are mice with human EHE tissue implanted to keep the tissue alive and allow it to grow); it is beginning to identify possible biomarkers; it will start to research genuine new therapeutic targets and drugs; and will also be initiating a major study of radiological imagery to try and improve our understanding of what these images are telling us about the progress of the disease in a patient. It has the potential to deliver game changing results in a number of key areas, something we are very happy to be able to help fund.

We look forward to reporting on this exciting project in the future.